Shots:

• The global P-III HARMONIZE involves assessing of Lokelma (5/10mg) vs PBO in 267 patients with hyperkalaemia in Japan- Korea- Taiwan and Russia across 47 locations
• P-III HARMONIZE Results: @48 hrs.: Achieved normokalaemia (mean K level 3.5-5.0 mEq/L) 93%; safety was consistent with previous trials. These results will support its registration in Japan- Korea- Taiwan and Russia- are presented at ASN Kidney Week-2018
• Lokelma is currently approved in adults for hyperkalemia in the US & EU. In 2015- AZ acquired Lokelma from ZS pharma

Ref: AstraZeneca | Image: AstraZeneca